Bienvenido al Med Info Alert. En la siguiente página podrás encontrar información de interés sobre Psoriasis Pustulosa Generalizada, publicada entre marzo y mayo de 2023.
Si estás interesado en recibir alguna publicación de este mes, a continuación, puedes descargarla o acceder a tu cuenta para solicitarla.
Puig L, et al. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023.
Fukaura R, et al. Targeting IL-36 in Inflammatory Skin Diseases. BioDrugs. 2023.
Bellinato F, et al. Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study. Vaccines (Basel). 2023.
Patel PM, Sanchez-Melendez SN, Nambudiri VE. A narrative review of studies assessing the quality of life in patients with generalized pustular psoriasis. Exp Dermatol. 2023.
Choon SE, et al. Diversity in the clinical presentation of generalized pustular psoriasis (GPP): A series of case vignettes from around the world. Exp Dermatol. 2023.
Jaworecka K, et al. Characteristics of pruritus in various clinical variants of psoriasis: Final report of the binational, multicentre, cross-sectional study. J Eur Acad Dermatol Venereol. 2023.
Burden AD. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis. Expert Rev Clin Immunol. 2023.
Elewski BE, et al. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. J Am Acad Dermatol. 2023.
Burden AD, et al. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study. Exp Dermatol. 2023.
Navarini AA, et al. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study. J Eur Acad Dermatol Venereol. 2023.
Warren RB, et al. Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial. Br J Dermatol. 2023.
PC-ES-111082